Cullinan Therapeutics, Inc.
NASDAQ:CGEMMedical - Pharmaceuticals
Healthcare
$9.01 +4.29%
+$0.62 today
- Market cap
- $584.94M
- Beta
- 0.01
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$3.73
52W Low $5.68High $16.74
Volume 1.06M
Average 0.99M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$241.65M
FY 2025 · Annual
Net Income
-$219.88M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.94M | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 306K | 0 |
| Gross Profit | 18.94M | 0 | 0 | (306K) | 0 |
| Gross Margin | 100.0% | — | — | — | — |
| Research & Development | 57.75M | 91.95M | 148.16M | 142.9M | 187.4M |
| Selling, General & Admin | 29.15M | 40.19M | 42.49M | 53.71M | 54.25M |
| Operating Expenses | 86.9M | (144.65M) | 191.09M | 196.61M | 241.65M |
| Depreciation & Amortization | 53K | 93K | 310K | 306K | 311K |
| EBITDA | (67.43M) | (132.04M) | (190.34M) | (167.15M) | (219.57M) |
| EBITDA Margin | -356.0% | — | — | — | — |
| Operating Income | (67.95M) | 144.65M | (191.09M) | (196.92M) | (241.65M) |
| Operating Margin | -358.7% | — | — | — | — |
| Interest Income | 477K | 6.61M | 21.63M | 29.66M | 22.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 469K | 6.67M | 21.87M | 29.46M | 21.77M |
| Income Before Tax | (67.49M) | 151.32M | (169.22M) | (167.46M) | (219.88M) |
| Pre-Tax Margin | -356.3% | — | — | — | — |
| Income Tax Expense | 0 | 42.12M | (14.12M) | 117K | 0 |
| Net Income | (65.57M) | 111.21M | (153.16M) | (167.38M) | (219.88M) |
| Net Margin | -346.1% | — | — | — | — |
| EPS (Basic) | (1.48) | 2.46 | (3.69) | (3.11) | (3.72) |
| EPS (Diluted) | (1.48) | 2.38 | (3.69) | (3.11) | (3.72) |
| 44.29M | 45.16M | 41.51M | 53.77M | 59.05M | |
| 44.29M | 46.64M | 41.55M | 53.77M | 59.05M |
CGEM Earnings Waterfall · TTM
NASDAQ:CGEM · Revenue to Net Income
Key Ratios
EPS$-3.75
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.6
P/S Ratio0.0
Analysis
$0 of revenue converted into -$221.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.75, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 |
How much revenue does CGEM generate?
Cullinan Therapeutics, Inc. (CGEM) reported $0.00 of revenue in fiscal 2025.
Is CGEM profitable?
Cullinan Therapeutics, Inc. (CGEM) reported -$219.88M of net income.
Continue the stock analysis
Jump to another research area for this company.